Barclays PLC Announces New Share Buy-Back Program
Ticker: BCLYF · Form: 6-K · Filed: Oct 23, 2025 · CIK: 312069
| Field | Detail |
|---|---|
| Company | Barclays PLC (BCLYF) |
| Form Type | 6-K |
| Filed Date | Oct 23, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 3 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: share-buyback, capital-return
Related Tickers: BCS
TL;DR
Barclays launching new buy-back program, details TBD.
AI Summary
Barclays PLC announced on October 23, 2025, that it will commence a new share buy-back program. The company has not yet disclosed the specific amount or duration of this program, but it will be conducted in accordance with regulatory requirements and market conditions.
Why It Matters
This signals Barclays' confidence in its financial position and its commitment to returning capital to shareholders, potentially boosting share price.
Risk Assessment
Risk Level: low — The filing is an announcement of a planned buy-back program, which is a common corporate action and does not inherently indicate significant new risks.
Key Players & Entities
- Barclays PLC (company) — Registrant announcing buy-back program
- October 23, 2025 (date) — Date of the announcement
FAQ
When will the new share buy-back program commence?
The filing states that the program will commence in the future, but does not provide a specific start date.
What is the total value or number of shares intended for the buy-back program?
The filing does not specify the total value or number of shares to be repurchased under the new program.
Under which regulatory framework is this buy-back program being conducted?
The buy-back program will be conducted in accordance with applicable regulatory requirements and market conditions.
Has Barclays PLC previously conducted share buy-back programs?
While not explicitly stated in this filing, the announcement of a 'new' program implies previous buy-back activities.
Where can shareholders find more information about the buy-back program?
Further details are expected to be provided by Barclays PLC in accordance with regulatory requirements and market conditions.
Filing Stats: 745 words · 3 min read · ~2 pages · Grade level 20 · Accepted 2025-10-23 07:01:56
Filing Documents
- a4632e.htm (6-K) — 20KB
- 0001654954-25-012076.txt ( ) — 21KB
SIGNATURES
SIGNATURES       Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.       BARCLAYS PLC   (Registrant)       Date: October 23, 2025       By: /s/ Garth Wright --------------------------------   Garth Wright   Assistant Secretary     23 October 2025   Barclays PLC   Future commencement of Buy-back   Barclays PLC (the " Company ") announces that, as disclosed in its announcement on 22 October 2025, it will commence a share buy-back programme to purchase ordinary shares of 25 pence each in the Company (" Ordinary Shares ") for up to a maximum consideration of £500m (the " Buy-back "). The Buy-back will commence on the business day (in London) immediately following completion of the £1,000m share buy-back programme commenced by the Company on 30 July 2025 and end no later than 20 April 2026 (subject to regulatory approval remaining in place). The purpose of the Buy-back is to reduce the share capital of the Company and therefore Ordinary Shares purchased under the Buy-back will be cancelled.   The Company has entered into an agreement with Citigroup Global Markets Limited (" Citi ") to conduct the Buy-back on its behalf and carry out on-market purchases of Ordinary Shares, acting as riskless principal, and to on-sell such Ordinary Shares to the Company.   Citi will make trading decisions in relation to the Buy-back independently of, and without further instruction from, the Company.  Any purchases of Ordinary Shares under the Buy-back will be carried out on the London Stock Exchange in accordance with certain pre-set parameters set out in the agreement with Citi and in accordance with (and subject to the limits prescribed by) the Company's gener